World Market for Prescription Generic Drugs, 6th Edition

Generics, so long the force that has shaken up the branded pharmaceutical industry, is now facing its own challenges as an industry. While growth indications are strong, there are challenges for generic companies. In the next two years, consolidation will most likely rise; the sector is expected to be rocked by increased competition from companies in Eastern Europe, India and China, as well as brand name companies seeking to protect their franchises by moving into generics.

Kalorama Information's World Market for Prescription Generic Drugs, 6th Edition is your guide to this formidable and important participant in the complex world of healthcare. Included are market size and forecast revnues for:

• Allergy and Respiaratory Drugs
• Analgesics, NAIDS, and Antirheumatic Drugs
• Anesthesia Drugs
• Anti-Infectives
• Cancer Drugs
• Cardiovascular Drugs
• Central Nervous System and Psychotherapeutic Drugs
• Gastrointestinal Drugs
• Ophthalmic Drugs

This report is the result of primary research and secondary research. Interviews with experts in the generic industry form the basis of this report. Research was conducted from available company reports, trade publications and medical and government databases. Interviews with experts are the source of models.

For each drug segment, the report provides:

• Estimated Generic Market Size
• Forecast to 2012
• Recent ANDA Approvals
• World and US Market Share
• Company Profiles

Knowledge of the issues that face the generics industry is essential to understanding the market. The report discusses the following trends:

• Legislative Issues
• Big Pharma Tactics
• Authorized Generics
• Generic Biologics
• Medicaid Generic Drug Reimbursement
• The Elderly
• Confusion in Generic Names
• Broadening Generic Horizons
• International Generic Drug Issues
• Indian Drug Makers
• Industry Consolidation
• New Generic Giants
• Patent Issues
• Generic Companies Increasingly Aggressive
• Patent Reform
• Generic Growth
• Generic Statins
• Cost
• Generics Improve Compliance
• Generic Drug Sampling

Marketing executives, business development managers and brand and generic pharmaceutical companies, consultants and investors are among those who will benefit from this report.